Please login to the form below

Not currently logged in
Email:
Password:

Merck’s CEO Kenneth Frazier to retire after ten years in the role

Frazier is handing the reins over to current Merck CFO Robert Davis

Merck & Co’s chief executive officer (CEO) Kenneth Frazier (pictured left) is set to retire, ten years after taking the helm at the pharma giant.

Frazier joined Merck in 1992 as vice president, general counsel and secretary of the Astra Merck group.

Since then, he has advanced in the company, holding increasingly senior roles across the organisation, ultimately being appointed president of Merck in May 2010.

In January 2011, he took on the role of CEO and also became chairman of the board in December of that year.

Under his leadership, Merck has seen impressive growth for its immunotherapy blockbuster Keytruda (pembrolizumab) and other innovative treatments.

Frazier is a strong advocate for social and economic inclusion, having received numerous awards and honours including the Anti-Defamation League Courage Against Hate Award, the Botwinick Prize in Business Ethics from Columbia Business School and more.

He was named one of the World’s Greatest Leaders by Fortune Magazine in 2019, and also became the first recipient of the Forbes Lifetime Achievement Award for Healthcare in 2019.

Frazier is handing over the CEO reins to Robert Davis, who is currently chief financial officer (CFO) at Merck.

Prior to Merck, Davis (pictured right) was corporate vice president and president of Baxter’s Medical Products business.

He joined Merck in 2014 as CFO, with his role being further expanded in 2016 to include the company’s global support functions.

This encompassed corporate business development, investor relations, information technology, procurement, real estate operations and corporate strategy.

After retiring as CEO, Frazier will continue to serve on Merck’s board of directors as executive chairman.

“It has been a privilege to serve as Merck’s CEO for the past decade and to work with the most dedicated and talented employees and management team in the industry,” said Frazier.

“As executive chairman, I look forward to collaborating with Rob [Davis] and our board of directors to help Merck achieve even higher levels of success,” he added.

Article by
Lucy Parsons

5th February 2021

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics